Nothing Special   »   [go: up one dir, main page]

ES2163501T3 - Agente para la disminucion de la tension ocular. - Google Patents

Agente para la disminucion de la tension ocular.

Info

Publication number
ES2163501T3
ES2163501T3 ES95912428T ES95912428T ES2163501T3 ES 2163501 T3 ES2163501 T3 ES 2163501T3 ES 95912428 T ES95912428 T ES 95912428T ES 95912428 T ES95912428 T ES 95912428T ES 2163501 T3 ES2163501 T3 ES 2163501T3
Authority
ES
Spain
Prior art keywords
group
alkyl
formula
alkenyl
carboxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912428T
Other languages
English (en)
Inventor
Tomihisa Yokoyama
Tsunemichi Hosokawa
Hiroaki Yanagisawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2163501T3 publication Critical patent/ES2163501T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)

Abstract

UN AGENTE EXCELENTE REDUCTOR DE LA TENSION OCULAR Y/O AGENTE TERAPEUTICO DE GLAUCOMAS PARA GOTAS DE OJOS QUE CONTIENE EL COMPUESTO MOSTRADO ABAJO, UNA SAL DEL MISMO Y/O ESTER DEL MISMO. [R{SUP,1}: ALKILO, ALQUENILO, UN GRUPO DE LA FORMULA R{SUP,5}-AB-(R{SUP,5}: H, ALKILO, CICLOALKILO, ACILO; A: O, S; B: ENLACE SENCILLO, ALQUILENO); R{SUP,2}: ALQUILO, ALQUENILO, UN GRUPO DE LA FORMULA C(R{SUP,6}(R{SUP,7})(R{SUP,8}) (R{SUP,6}: OH, ALCOXI; R{SUP,7}, R{SUP,8}: H, ALQUILO, ALQUENILO, ALQUINILO, CICLOALKILO, ARILO, ARALKILO); R{SUP,3}: COOH, UN GRUPO DE LA FORMULA -CON(R{SUP,9})(R{SUP,10}) (R{SUP,9}, R{SUP,10}: H, ALKILO OPCIONALMENTE SUSTITUIDO); R{SUP,4}: COOH, COCOOH, TETRAZOL]
ES95912428T 1994-03-16 1995-03-16 Agente para la disminucion de la tension ocular. Expired - Lifetime ES2163501T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4540494 1994-03-16

Publications (1)

Publication Number Publication Date
ES2163501T3 true ES2163501T3 (es) 2002-02-01

Family

ID=12718322

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01102527T Expired - Lifetime ES2221872T3 (es) 1994-03-16 1995-03-16 Agente para la disminucion de la tension ocular.
ES95912428T Expired - Lifetime ES2163501T3 (es) 1994-03-16 1995-03-16 Agente para la disminucion de la tension ocular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01102527T Expired - Lifetime ES2221872T3 (es) 1994-03-16 1995-03-16 Agente para la disminucion de la tension ocular.

Country Status (20)

Country Link
US (1) US5925664A (es)
EP (2) EP0795326B1 (es)
KR (1) KR100211446B1 (es)
CN (2) CN1104898C (es)
AT (2) ATE206050T1 (es)
AU (1) AU684916B2 (es)
CZ (1) CZ284395B6 (es)
DE (2) DE69522955T2 (es)
DK (2) DK0795326T3 (es)
ES (2) ES2221872T3 (es)
FI (2) FI114897B (es)
GR (1) GR3036989T3 (es)
HK (1) HK1000551A1 (es)
HU (1) HUT74734A (es)
MX (1) MX9604109A (es)
NO (1) NO311068B1 (es)
NZ (1) NZ282485A (es)
PT (2) PT795326E (es)
RU (1) RU2123847C1 (es)
WO (1) WO1995024902A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100611543B1 (ko) * 1999-06-11 2006-08-10 상꾜 가부시키가이샤 국소 투여용 안압 저하 조성물
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
GR20000100281A (el) * 2000-08-17 2002-05-24 Ιωαννης Ματσουκας Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
CA2522318C (en) * 2003-04-15 2011-09-13 Sankyo Company Limited Drug for preventing or treating angiogenic eye diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
CA2060656A1 (en) * 1989-06-30 1990-12-31 Robert John Ardecky Substituted imidazoles
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
FI112942B3 (fi) * 1991-02-21 2012-03-13 Daiichi Sankyo Co Ltd Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
DK0573218T3 (da) * 1992-06-02 2001-06-18 Sankyo Co 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists

Also Published As

Publication number Publication date
AU1960295A (en) 1995-10-03
RU2123847C1 (ru) 1998-12-27
EP0795326A1 (en) 1997-09-17
HU9602534D0 (en) 1996-11-28
CZ269496A3 (en) 1996-12-11
HUT74734A (en) 1997-02-28
NZ282485A (en) 1997-06-24
EP1110551A2 (en) 2001-06-27
NO963854D0 (no) 1996-09-13
EP0795326B1 (en) 2001-09-26
US5925664A (en) 1999-07-20
MX9604109A (es) 1997-09-30
FI963645A0 (fi) 1996-09-16
CN1387846A (zh) 2003-01-01
DE69522955D1 (de) 2001-10-31
CZ284395B6 (cs) 1998-11-11
PT1110551E (pt) 2004-07-30
CN1104898C (zh) 2003-04-09
GR3036989T3 (en) 2002-01-31
FI115197B (fi) 2005-03-31
HK1000551A1 (en) 2002-04-12
DE69533045D1 (de) 2004-06-17
NO963854L (no) 1996-11-14
DE69533045T2 (de) 2005-01-27
CN1202819C (zh) 2005-05-25
ES2221872T3 (es) 2005-01-16
EP0795326A4 (es) 1997-09-17
KR100211446B1 (ko) 1999-08-02
ATE206050T1 (de) 2001-10-15
KR970701542A (ko) 1997-04-12
DK0795326T3 (da) 2001-11-26
EP1110551B1 (en) 2004-05-12
FI114897B (fi) 2005-01-31
NO311068B1 (no) 2001-10-08
DK1110551T3 (da) 2004-06-07
PT795326E (pt) 2002-01-30
AU684916B2 (en) 1998-01-08
FI20041236A (fi) 2004-09-24
EP1110551A3 (en) 2001-08-16
FI963645A (fi) 1996-11-14
DE69522955T2 (de) 2002-05-29
ATE266402T1 (de) 2004-05-15
WO1995024902A1 (fr) 1995-09-21
CN1148809A (zh) 1997-04-30

Similar Documents

Publication Publication Date Title
KR950032169A (ko) 안약 조성물
DK0628311T3 (da) Xanthinderivater som antidepressive midler
DE69116909D1 (de) 3,5-Di-tertiärbutyl-4-hydroxyphenylmethylenderivate von 2-substituierten Thiazolidinonen, Oxazolidinonen und Imidazolidinonen als antientzündlich wirkende Mittel
ES2070186T3 (es) Nuevos derivados de 2,4-diamino-pirimidina-3-oxido y su utilizacion en la prevencion de la caida de los cabellos.
DE69716226D1 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
ATE194335T1 (de) 4,5-diaryloxazol-derivate
DE69208478D1 (de) Amid derivate von vitamin d
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
ATE227710T1 (de) Oxazole derivate,ihre herstellung und verwendung
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
ES2163501T3 (es) Agente para la disminucion de la tension ocular.
ATE56967T1 (de) Amidderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 795326

Country of ref document: ES